Navigation Links
WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Date:3/1/2011

ividual patients' predispositions to major diseases as well as the therapeutic considerations that can improve treatment outcomes and quality of life.
With its growing portfolio of genetics-based tests and assays, the company is addressing one of today's major medical challenges by ushering in a new era of more timely, predictive, and affordable "personalized" healthcare.  The Company markets the Warfarin GenoSTAT Test® to provide personalized genetic profiles of patients' potential responses to treatment with warfarin.  Iverson Genetic Diagnostics is headquartered in Bothell, Washington, part of the greater Seattle technology corridor.  The company's facilities are CLIA- and CAP-certified.  For more information, visit  www.IversonGenetics.com.Lynn Blenkhorn508-851-0930Lynn.blenkhorn@fkhealth.com
'/>"/>
SOURCE Iverson Genetic Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genetic information personalizes warfarin prescribing
2. Pivotal Study Validates Roches cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
3. Georgia Health Sciences University Clinical Study Shows RyMed InVision-Plus® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
4. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
5. Study Confirms Third Trimester Amniotic Fluid a Reliable Source of Stem Cells for Regenerative Medicine and Stem Cell Banking
6. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
7. New test to study proteins involved in neurodegenerative diseases
8. A new model for studying Parkinsons
9. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
10. Columbia University researchers use nanoscale transistors to study single-molecule interactions
11. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Biosciences,Corporation (Nasdaq: MATK ) today announced that ... Wilmington, Delaware, has ruled on various,post-trial motions and ... the defendants in the patent infringement suit brought ... Nutrition Specialties &,Food Ingredients GmbH. The suit involves ...
... Nov. 1 ThermoGenesis,Corp. (Nasdaq: KOOL ), a ... store, and administer therapeutic doses of,adult stem cells for ... financial results for the fiscal first quarter ended September,30, ... Call and Webcast Management will host a conference ...
... technical feasibility of ... ... TSX symbol: SBS, CALGARY, Nov. 1 /PRNewswire-FirstCall/ - ... for metabolic and cardiovascular diseases, today announced its,2007 third quarter operational ...
Cached Biology Technology:Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 3ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 3SemBioSys announces 2007 third quarter results 2SemBioSys announces 2007 third quarter results 3SemBioSys announces 2007 third quarter results 4SemBioSys announces 2007 third quarter results 5SemBioSys announces 2007 third quarter results 6SemBioSys announces 2007 third quarter results 7SemBioSys announces 2007 third quarter results 8SemBioSys announces 2007 third quarter results 9SemBioSys announces 2007 third quarter results 10SemBioSys announces 2007 third quarter results 11SemBioSys announces 2007 third quarter results 12
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with ... device of Apple incorporating such a feature, called ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ... to expand its team and bring LaunchKey to market ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... high blood pressure drugs may be useful in preventing and ... people with diabetes. The study, the largest to date on ... prevent or treat the sight-threatening disease, they say. The findings ... monthly publication. Edward Feener and colleagues point out ...
... Pneumonia A group led by Dr. James ... Human Infectious Diseases Research of The Methodist Hospital Research ... Paton-Valentine leukocidin (PVL) does not affect methicillin-resistant Staphlococcus ... can be found in the March 2010 issue of ...
... -- Oak Ridge National Laboratory researchers will lead projects ... processor hours of computing time on supercomputers located at ... awards were made through the U.S. Department of Energy ... Experiment (INCITE) program. This year, the INCITE program will ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 52010 DOE INCITE projects allocated at ORNL 22010 DOE INCITE projects allocated at ORNL 32010 DOE INCITE projects allocated at ORNL 4
Guanine nucleotide-binding protein G(k), alpha subunit...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Indoleamine 2,3-dioxygenase [IDO]...
Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....
Biology Products: